{"doi":"10.1093/cid/ciad162","title":"Vaccination of Older Adults Against Respiratory Syncytial Virus: The Final Pieces of the Puzzle","abstract":"With an estimated 186,000-614,000 older adults hospitalised annually as a result of respiratory syncytial virus (RSV) infection and with no effective treatment, there is an unmet need to prevent these infections, many of which lead to death [1].Fortunately, we are in a golden age of RSV vaccine development with five formulations targeting older adults currently emerging from phase III trials [2].With favourable trial results appearing, policy makers are now asking crucial questions about how we will use these new pharmaceuticals to improve the health of our elderly population: which vaccine product should we use? should our vaccine campaign be seasonal?do we need annual boosters?which age group should be eligible?Answers to these questions will rely in part on using mathematical models to project the population impact of each vaccine.Consequently, mathematical models have become an indispensable part of the policy maker's evidence toolkit.Indeed, one of the benefits of mathematical models is that they can capture the considerable uncertainty in both the epidemiology of RSV disease and the protection afforded by potential vaccines.Van Effelterre et al. [3] use a mathematical model of RSV transmission to capture this uncertainty to predict the impact of an RSV vaccination programme targeted at adults 60 years and over in the United States.The study uses a Bayesian framework to incorporate existing knowledge on the epidemiology of RSV.The mathematical model itself is an adaptation of a previously published model that captures the uptick in older adult RSV incidence by assuming an elevated risk of disease","journal":"Clinical Infectious Diseases","year":2023,"id":378472,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9547,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":729919,"name":"David Hodgson","orcid":"0000-0002-5585-8974","position":1,"is_corresponding":false},{"id":960666,"name":"Katherine E. Atkins","orcid":"0000-0001-5250-0558","position":0,"is_corresponding":true}],"reference_count":8,"raw_metadata":null,"created_at":"2026-07-19T01:16:44.708019Z","pmid":"36949619","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}